Skip to content
Biotron Limited
  • Home
  • About Us
    • Board of Directors
    • Management Team
  • Technology
    • Clinical programs
    • Non-clinical programs
    • Intellectual property
  • News/Resources
    • Newsletters
    • In the news
    • Scientific Presentations
    • Scientific Publications
  • Investor Centre
    • ASX Announcements
    • Financial Reports
      • Annual
      • Half-year
      • Quarterly
    • Corporate Directory
    • Shareholder services
    • Options Exercise Instructions
    • Top 40 Shareholders
    • Corporate Governance
    • Corporate Presentations
  • Contacts

Presentation of BIT225 Hepatitis C Virus 48-week data at AASLD conference, Boston MA

28 February 201416 November 2012 by Karen Mobbs

Presentation of BIT225 Hepatitis C Virus 48-week data at AASLD conference, Boston MA

Categories Scientific Presentations
Post navigation
Key Phase 2 HIV/HCV trial commenced
Commencement of three-month toxicology studies for BIT225
© Biotron Limited 2016       ABN 60 086 399 144        Site updated 28 July 2022        Legal Notices and Privacy